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Abstract Little is known about frequency, association
with clinical characteristics, and prognostic impact of DNA
copy number alterations (CNA) on survival in central
primitive neuroectodermal tumors (CNS-PNET) and
tumors of the pineal region. Searches of MEDLINE, Pub-
med, and EMBASE—after the original description of
comparative genomic hybridization in 1992 and July
2010—identified 15 case series of patients with CNS-
PNET and tumors of the pineal region whose tumors were
investigated for genome-wide CNA. One additional case
study was identified from contact with experts. Individual
patient data were extracted from publications or obtained
from investigators, and CNAs were converted to a digitized
format suitable for data mining and subgroup identification.
Summary profiles for genomic imbalances were generated
from case-specific data. Overall survival (OS) was esti-
mated using the Kaplan–Meier method, and by univariable
and multivariable Cox regression models. In their overall
CNA profiles, low grade tumors of the pineal region clearly
diverged from CNS-PNET and pineoblastoma. At a median
follow-up of 89 months, 7-year OS rates of CNS-PNET,
pineoblastoma, and low grade tumors of the pineal region
were 22.9 ± 6, 0 ± 0, and 87.5 ± 12 %, respectively.
Multivariable analysis revealed that histology (CNS-
PNET), age (B2.5 years), and possibly recurrent CNAs
were associated with unfavorable OS. DNA copy number
profiling suggests a close relationship between CNS-PNET
and pineoblastoma. Low grade tumors of the pineal region
differed from CNS-PNET and pineoblastoma. Due to their
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high biological and clinical variability, a coordinated
prospective validation in future studies is necessary to
establish robust risk factors.
Keywords Chromosomal imbalances  Prognostic
markers  Comparative genomic hybridization 
Brain tumor
Introduction
Central nervous system primitive neuroectodermal tumors
(CNS-PNET) are a heterogeneous group of WHO grade IV
lesions (Supplementary Table 1). They comprise 3–7 % of
brain tumors in children and young adults [1, 2] and are
associated with a dismal prognosis [3, 4]. Histologically,
these highly proliferative lesions are currently divided into
CNS-PNET or supratentorial PNET, respectively (syno-
nym PNET not otherwise specified, PNET NOS), CNS
neuroblastoma, CNS ganglioneuroblastoma, medulloepi-
thelioma, and ependymoblastoma [5]. CNS-PNET and
medulloblastoma share a similar histology and are often
solely distinguishable by their supratentorial versus infra-
tentorial location. Further, pineoblastoma, a WHO grade
IV tumor of the pineal gland [5], is filed in some studies as
CNS-PNET although pineoblastoma forms a group of
neoplasms of the pineal region together with pineocytoma,
pineal parenchymal tumor of intermediate differentiation,
and papillary tumor of the pineal region [5]. The classifi-
cation of malignancies within the group of embryonal
tumors has changed considerably in the last four editions
of the WHO classification of tumors of the CNS (Supple-
mentary Table 1). Tumor classification systems are
increasingly complemented by molecular genetic profiling
data, especially in hematologic neoplasias [6]. However,
for the various subtypes of CNS-PNET, such data are still
scarce and large series are missing. Profiling of regional
copy number abnormalities (CNA) by genomic hybridiza-
tion techniques is a robust methodology for whole genome
data analysis. Principal techniques include the different
variants of chromosomal and array-based comparative
genomic hybridization (cCGH/aCGH; [7–10]) and single-
color oligonucleotide array technologies [e.g., genomic
single nucleotide polymorphism (SNP) arrays].
In contrast to data from gene expression measurements,
CGH data is easily adaptable across multiple datasets to per-
form a meta-analysis. Methods to assess genomic CNAs are
standardized and reproducible as demonstrated in previous
reports (e.g., [11, 12]). Some earlier reviews have reported on
specific types of aberrations or were focused on the descriptive
analysis of certain classes of malignancies [13, 14].
Due to the low incidence of CNS-PNET and pineo-
blastoma, only a few CGH studies have been reported in
these tumors [2, 15–17]. So far, results have suggested that
CNS-PNET are genetically heterogeneous with frequent
and diverse CNAs and that CNA patterns are distinct from
those observed in medulloblastoma [2, 15–17].
For the present study, we performed an individual
patient data (IPD) meta-analysis—a specific method of
systematic review [18] offering advantages for meta-anal-
ysis [19, 20]—of genomic imbalances in CNS-PNET and
tumors of the pineal region. The collected data are made
available through the ‘‘Progenetix’’ molecular-cytogenetic
database (www.progenetix.org: [14, 21, 22]).
Methods
Search strategy, and selection criteria
We did a modification of the Cochrane Highly Sensitive Search
Strategy for prognostic studies [20] combined with predefined
search terms in MEDLINE, Pubmed, and EMBASE without
language restriction [23, 24]. The process of the study retrieval,
in- and exclusion of studies/patients is displayed in the flow
chart (Supplementary Fig. 1) according to the PRISMA (pre-
ferred reporting items for systematic reviews and meta-analy-
ses) statement. The search was limited to articles published after
the original description of CGH [7] until July 2010. Key words
were: ‘‘medullo(-)blastoma(s)’’, ‘‘primitive neuroectodermal
tumo(u)r(s)’’, ‘‘neuroectodermal tumo(u)r(s) primitive’’ ‘‘pnet
(s)’’, ‘‘medullo(-)epithelioma(s)’’, ‘‘ependymoblastoma(s)’’,
‘‘ganglioneuroblastoma(s)’’, ‘‘pinealoma’’, ‘‘pineocytoma(s)’’,
‘‘pineoblastoma(s)’’, ‘‘pineal tumo(u)r(s)’’, ‘‘pineal parenchy-
mal tumo(u)r(s)’’, ‘‘mixed transitional pineal tumo(u)r(s)’’,
‘‘mixed transitional pineal tumo(u)r(s)’’, ‘‘atypical teratoid
rhabdoid tumo(u)r(s)’’, ‘‘rhabdoid tumo(u)r(s)’’, ‘‘AT(/)RT’’
and ‘‘rhabdoid’’, ‘‘supratentorial neoplasm(s)’’ or ‘‘neuroblas-
toma(s)’’ and ‘‘central nervous system neoplasm(s)’’; and
‘‘cgh’’ or ‘‘comparative genomic hybridization’’ or ‘‘snp’’ or
‘‘SNP’’ or ‘‘genomic array(s)’’ or ‘‘copy number’’ or ‘‘dna
microarray(s)’’ or ‘‘amplification’’. Additionally to the search
queries, we followed references from the selected articles and
assessed each abstract. Minimal requirements for inclusion of a
patient to the study were the availability of case-specific
genomic copy number data with whole genome coverage, the
unambiguous diagnostic classification of CNS-PNET/tumor of
the pineal region, and matching available or inferred locus
information.
Fig. 1 Delineation of 3 distinct clinicogenetic subgroups. a Regional
copy number imbalances for individual cases were plotted separately
by overall diagnostic assignment [yellow gain, blue loss, blue tumors
of the pineal region except pineoblastoma, light blue pineoblastoma,
pink central primitive neuroectodermal tumors (CNS-PNET)]. Indi-
vidual profiles were arranged by hierarchical clustering inside their
groups. b Histograms of genomic gain and loss frequencies (color
legend corresponding to (a))
c
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Clinical and CNA data collection, data extraction,
quality assessment, conversion of CNA data,
and data synthesis
For CGH results specified in cytogenetic annotation for-
mats, data were standardized to ISCN 1995 (International
System for Human Cytogenetic Nomenclature, 1995) ‘‘re-
vish’’ format based on an 862-bands karyotype and
checked for semantically correct annotation using dedi-
cated software. For genomic array data without annotated
gain/loss information, clone specific data files were seg-
mented using Progenetix website tools. Normalized data
were converted to Golden Path mapped copy number status
information by software implemented in the Perl scripting
language [14].
In a first step, clinical and genomic data were extracted
from publications by two reviewers (A.O.V.B. and M.B.).
Subsequently, the original data, in particular in case of
incomplete data (genomic and clinical data), for each par-
ticipant were obtained and updated directly from the
researcher responsible for each included study [25]. To
prevent duplicate inclusions, authors were asked to indicate
whether a patient had been analyzed within different studies.
In addition, copy number profiles were clustered for simi-
larity and reviewed for the occurrence of profile pairs, in
order to avoid duplicate cases due to republished data. Data
of three unpublished CNS-PNET patients were provided by
two authors (S.P. and O.D.). Generally, two approaches to
perform IPD meta-analyses are used. First, IPD meta-anal-
yses can be performed directly, as if all data belong to a
single trial/study, termed the ‘‘one-stage’’ approach [26].
Second, a ‘‘two-stage’’ approach can also be used. Each trial/
study is analyzed separately using its raw data before the
summary results from each trial/study are pooled and ana-
lyzed using conventional meta-analyses techniques [26].
Due to the small patient numbers of each individual case
series, the ‘‘one-stage’’ approach was used here.
Exploratory data mining and statistical analysis
For the evaluation of regional copy number changes, non-
overlapping genomic segments were generated based on
the complete CNA data from all cases. For each of these
intervals, case-specific involvement was evaluated and
gain/loss frequencies determined. For visualization and
ordering of case-specific CNA data, data matrices were
produced containing imbalance status (gain, or loss) map-
ped to a variety of genomic intervals (from chromosomal
arm level down to 1 Mb). Cases were ordered by hierar-
chical clustering of gain/loss matrices (unsupervised,
complete linkage), and the derived case order was used
for re-plotting of the original CNA annotations. CNA
complexity, a relatively resolution-independent surrogate
marker of genomic instability, was determined for each
case by evaluating the occurrence of gain and loss events
per chromosome arm, with a maximum score of 2 per arm
(i.e. occurrence of one or more of each gain and loss;
modified from [27]).
To evaluate imbalance distribution in relation to diag-
nostic assignment, for each of the entities in our dataset, gain/
loss frequencies were calculated mapped to genomic inter-
vals on a 5-Mb level. Copy number profiles were compared
by generating a heatmap of gain/loss distributions.
Cases with clinical follow-up were evaluated with
respect to correlation of clinical factors and regional CNA
status to OS. OS was defined as date of diagnosis to death
of any cause or to the date of last visit. Cut-off values of
age and CNA complexity were determined by recursive
partitioning [28]. Univariable and multivariable survival
analyses were performed. OS was estimated by the Kap-
lan–Meier method, and the log-rank test was used for
comparisons of survival in different groups [29]. Univari-
able analyses to investigate the effect of age (continuous),
and CNA complexity (continuous) on OS was done with
univariable Cox regression analysis. Multivariable analyses
were performed using Cox’s proportional hazards model.
All statistical analyses are intended to be rather exploratory
than confirmatory. p values are considered statistically
significant when p \ 0.05. No adjustment for multiple
testing was carried out. Statistical analyses were performed
using SAS (v.9.2 for Windows; SAS Institute, Cary,
NC, USA), and PASW Statistics 18 for Windows (SPSS,
Chicago, IL, USA).
Results
Supplementary Figure 1 illustrates the process of evaluat-
ing articles for inclusion in the IPD meta-analysis. We
identified 1,220 papers by the search terms. The number of
papers was reduced to 840 after removing of duplicates (by
titles and abstracts). Title and abstract review resulted in
the exclusion of 710 papers. Three case-specific data (one
case series) were provided by two authors. We reviewed
131 papers in full, from which 15 studies, and 1 unpub-
lished case series (n = 3), met inclusion criteria for this
study (Supplementary Fig. 1).
Study characteristics and quality assessment
The 16 studies included here comprised 107 patients in
total, after exclusion of 4 cases with ambiguous CNA
profiles. From 61 patients, information about OS was
available (clinical characteristics are shown in Table 1). Of
those, 38 patients were profiled using aCGH and 23
patients using cCGH. The median follow-up time for
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survivors was 75 months, and the median follow-up time
across all patients was 89 months. Fifteen children were
aged B2.5 years and 46 patients were aged[2.5 years. The
cohort compromised all tumor entities classified as CNS-
PNET in the current WHO classification when taking into
account the update of earlier WHO classification in which
some of these tumors were partly classified as different
subgroups of embryonal tumors [5, 30] (n = 46), and
tumors of the pineal region (n = 15) which included pin-
eocytoma (n = 4), pineal parenchymal tumor of interme-
diate differentiation (n = 3), papillary tumor of the pineal
region (n = 5), and pineoblastoma (n = 3). Mean CNA
complexity was 9.4 (range, 0.00–30.00). For the purpose of
statistical analysis, CNS-PNET were considered as one
group and tumors of the pineal region were considered as
another group.
Overall genomic imbalance patterns in central nervous
system primitive neuroectodermal tumors and tumors
of the pineal region
In order to evaluate the overall patterns of genomic
imbalances in bona fide CNS-PNET and tumors of the
pineal region, we visualized the case-specific CNAs of all
tumors clustered for their overall imbalance similarities
(Fig. 1a). In CNS-PNET (n = 88), frequent gains of
chromosomes 1q4 [n = 31 (35 %)], 2p2 [n = 27 (31 %)],
and 7q3 [n = 16 (18 %)] as well as losses involving
chromosome 13q2 [n = 21 (24 %)], and 6q [n = 18
(20 %)] could be observed among other less frequent
changes (Fig. 1b). In contrast, low grade tumors of the
pineal region were characterized by gains of chromosomes
4q2 [n = 6 (46 %)], and 12 [n = 5 [38 %)] as well as
losses of chromosomes 10 [n = 4 (31 %)), and 22 [n = 5
(38 %)]. Interestingly, pineoblastoma (n = 6) displayed a
pattern of genomic imbalances unrelated to the changes
observed in the group of low grade tumors of the pineal
region. Supplementary Figs. 2–4 illustrate gains and losses
of the different disease entities.
We observed frequent gains involving chromosome 2
and losses involving chromosome 6 in ependymoblastoma
as well as in medulloepithelioma (Supplementary Fig. 3b,
c). Losses of chromosome 6 and 13 were typical for
ependymoblastoma.
Embryonal tumor with abundant neuropil and true
rosettes (ETANTR) was first described by Eberhart et al.
[31], but is so far not listed as a distinct tumor entity in the
2007 WHO classification [5] and represents a CNS-PNET
with ‘‘ependymoblastic’’ rosettes [32]. Recently, Korshu-
nov et al. [33] demonstrated in a series of 21 ependymo-
blastoma and 20 ETANTR that 95 % of ETANTRs and
90 % of ependymoblastoma have the unique focal ampli-
fication at 19q13.42.
Therefore, the term embryonal tumor with multilayered
rosette (ETMR) has been suggested for ependymoblastoma
and ETANTR, a new entity with multilayered rosettes for
which amplification at 19q13.42 represents a rather sensi-
tive and specific marker [32].
In our cohort, we identified 9 tumors with such an
amplification. As described previously by Li et al. [2],
cases with such an amplification predominantly (8/9) also
displayed gains of the whole or the major part of chro-
mosome 2. For some additional cases with gain of chro-
mosome 2 identified by cCGH, no high-resolution data
were available. Therefore, we may not rule out an addi-
tional amplification at 19q13.42 in these cases.
Univariable and multivariable survival analysis
of clinical factors and CNA complexity
To assess which parameters contribute to prognosis, we
evaluated each clinical variable by univariable Kaplan–
Meier analysis. Tested variables were: gender, age, histol-
ogy (CNS-PNET vs. tumors of the pineal region), metastatic
stage (no metastases vs. metastases), extent of postoperative
residual disease (complete/gross total resection vs. residual
disease C1.5 cm2), radiotherapy (no radiotherapy/local
radiotherapy vs. cranio-spinal radiotherapy), chemotherapy
(no chemotherapy vs. chemotherapy), CNA complexity
(\11 vs C11 as defined by recursive partitioning), tumor
Table 1 Demographics and disease characteristics of 61 patients
with central primitive neuroectodermal tumors (CNS-PNET) and
tumors of the pineal region
Characteristics Number of patients
(complete follow-up;
n = 61)
Sex
Male 13 (21 %)
Female 17 (28 %)
N/A 31 (51 %)
Age
Median age at diagnosis
(range; years)
4.2 (0.6–66)
Histology
CNS-PNET 46 (75 %)
Tumors of the pineal region 15 (25 %)
Tumor samples source
Primary tumors 59 (97 %)
Relapses 2 (3 %)
Metastatic stage
Metastases 8 (13 %)
No metastases 21 (35 %)
N/A 32 (52 %)
N/A information not available
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sample source (primary tumor vs. relapse), and technique
(aCGH vs. cCGH). Supplementary Table 2 illustrates the
factors (histology, CNA complexity, and age) showing dif-
ferences as assessed by univariable analysis. Patients with
tumors of the pineal region had a more favorable OS when
compared to patients with CNS-PNET (7-year OS:
64.7 ± 15 vs. 22.9 ± 6 %, p = 0.007). Of note, all three
patients with a pineoblastoma and available follow-up were
dead 33 months after diagnosis, whereas all other patients
with low grade tumors of the pineal region had excellent
outcome (7-year OS: 87.5 ± 12 %). Patients aged
B2.5 years had unfavorable OS when compared to patients
aged [2.5 years (7-year OS: 0 ± 0 vs. 41.3 ± 8 %,
p = 0.001). OS rates were similar in CNS-PNET patients
with and without the amplification at 19q13.42. Univariable
cox regression analysis confirmed that increasing age
(continuous variable) is denoting a more favorable OS
[hazard ratio, 0.967 (per year); 95 % confidence interval,
0.939–0.996; p = 0.0282] and increasing CNA complexity
(continuous variable) a less favorable OS [hazard ratio,
1.063 (per unit); 95 % confidence interval, 1.012–1.117;
p = 0.0153]. Multivariable analysis of clinical factors and
CNA complexity revealed that histology (tumors of the
pineal region), age (older than 2.5 years) and CNA com-
plexity\11 are favorable prognostic factors (Table 2).
Multivariable survival analysis of chromosomal
aberrations, CNA complexity, and clinical factors
To identify which of the chromosomal aberrations might
have an impact on OS, multivariable survival analyses were
applied to all 61 patients incorporating the significant clinical
factors (histology and age), CNA complexity, as well as 75
different chromosomal gains and 75 different chromosomal
losses in a stepwise approach, respectively. These analyses
finally revealed that young age (B2.5 years), histology
(CNS-PNET), and recurrent gains of 3p1 (n = 3; 5 %), 13q1
(n = 5; 8.2 %), and 15q2 (n = 8; 13.1 %) are associated
with an increased risk for unfavorable OS (Table 3).
Discussion
Over recent years, whole genome/transcriptome molecular
analysis has led to the identification of divergent biological
characteristics in what were considered single cancer types.
In the field of pediatric neuro-oncology, medulloblastoma
are now considered as a group of biologically differing
entities consisting of at least 4 molecular subgroups,
loosely connected through their topography (cerebellum)
and partially overlapping histological appearance [34–42].
Molecular studies in rare tumor entities are severely
limited due to the low number of cases included in single
series, as well as conceptual and technical heterogeneity of
the studies. To our knowledge, our study is the first IPD
meta-analysis assessing the genomic and clinical features
in CNS-PNET and tumors of the pineal region and their
impact on OS. In this study, we show that CNS-PNET and
pineoblastoma are divergent in their CNA profiles when
compared with low grade tumors of the pineal region. For
the cases analyzed here, recurring CNA observed only in
low grade tumors of the pineal region were, e.g., gains on
Table 2 Multivariable
analyses of clinical prognostic
factors (n = 61) for overall
survival (OS)
CNS-PNET Central primitive
neuroectodermal tumor, Non
CNS-PNET tumors of the pineal
region, CNA copy number
aberrations, HR OS Hazard ratio
overall survival
Parameter Comparison Sample
size
HR OS 95 % Confidence
interval
P value
Histology Non CNS-PNET 15 0.312 0.109–0.891 0.0296
CNS-PNET 46
Age group (years) [2.5 46 0.386 0.197–0.757 0.0056
B2.5 15
CNA complexity C11 CNA 23 1.790 0.943–3.400 0.0752
\11 CNA 38
Table 3 Multivariable
analyses of clinical factors and
recurrent chromosomal
aberrations (forward stepwise
selection; n = 61) for overall
survival
Parameter Sample
size
Hazard ratio
overall survival
95 % Confidence
interval
P value
Age (C2.5 years) 46 0.295 0.141–0.619 0.0012
Histology (tumor of the
pineal region)
15 0.120 0.029–0.498 0.0035
seg3p1_gain 3 8.759 1.778–43.159 0.0077
seg13q1_gain 5 4.128 1.192–14.303 0.0253
seg15q2_gain 8 4.338 1.614–11.665 0.0036
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4q2, 9p, 12p, and 8q2 as well as deletions of chromosome
10. In contrast, recurring CNA only found in pineoblas-
toma were deletions on 4q, chromosome 9, and 1p3. Based
on our results, CGH analysis might be of help—in addition
to neuroradiological and histopathological evaluation—to
differentiate between CNS-PNET, pineoblastoma, and
lower WHO grade tumors of the pineal region. While
detection of the listed aberrations may be indicative for
assignment to one of the diagnostic groups, development of
a CNA-based classifier will ideally require larger numbers
of genome profiles.
We found evidence that younger age at time of diag-
nosis is a negative prognostic factor for OS, confirming
several previous studies reporting on poor outcome of
young children with CNS-PNET/pineoblastoma [3, 43].
Timmermann et al. [3] reported on OS and progression-free
survival rates after 3 years of 17.2 and 14.9 %, respec-
tively. Administration of radiotherapy was the only sig-
nificant prognostic marker (15 out of 29 patients were not
irradiated) in this study [3] suggesting that omitting the
radiotherapy in young children—with the goal to reduce
neurologic sequelae—might at least explain partly the
extremely poor outcome of young children with CNS-
PNET/pineoblastoma.
In our cohorts, CNS-PNET and pineoblastoma shared an
unfavorable prognosis. Small numbers of pineoblastoma (3
out of 61 patients) may limit the comparison of those two
tumor entities. Based on the literature, there is some evi-
dence that patients with pineoblastoma may do better than
patients with CNS-PNET [44, 45]. Patients with low grade
tumors of the pineal region had a favorable outcome (7-
year OS: 87.5 ± 12 %) confirming that those tumor enti-
ties need a less aggressive treatment than CNS-PNET/
pineoblastoma.
CNS-PNET and tumors of the pineal region share a
complex karyotype with frequent CNAs [46]. In our series
of 107 patients, low grade tumors of the pineal region
showed relative frequently absence of CNAs (4/13), less
frequently in pineoblastoma (1/6), and CNS-PNET (2/88).
Recently, a new entity of CNS-PNET termed ETMR has
been suggested for a subgroup of CNS-PNET (ependy-
moblastoma and ETANTR) for which amplification at
19q13.42 represents a rather sensitive and specific marker
[32]. Korshunov et al. [33] identified in the great majority
of ependymoblastoma and ETANTR the focal amplifica-
tion at 19q13.42 whereas such an amplification was not
observed in a large series of other pediatric brain tumors
[32]. As we report about cCGH and aCGH data, the fre-
quency of tumors with amplification at 19q13.42 (Supple-
mentary Fig. 6) should be interpreted with caution as
detection of the amplification at 19q13.42 might be missed
when tumors are profiled by conventional cCGH, which
has a spatial resolution limited of several megabases.
Patients with 19q13.42 amplified tumors had a relatively
poor OS (6/7 patients with available follow-up died of
disease). Of note, the analysis of the prognostic impact of
the amplification at 19q13.42 is limited in our cohort,
because—as mentioned above—this amplification might be
missed in tumors analyzed with cCGH.
Our results provide evidence that high CNA complexity
is an unfavorable prognostic marker in our cohort. Because
of high frequencies of genomic imbalances as well as
heterogeneous patterns and frequencies of CNAs, CNA
complexity appears to be a good measure for overall
genomic instability which may reflect aggressiveness of a
certain tumor. In light of this, specific recurrent genomic
imbalances which have been identified as CNAs with
potential impact on OS in our analyses [e.g., in the 61
patients: gain of seg3p1 (n = 3), seg13q1 (n = 5), seg15q2
(n = 8)], need to be validated—ideally in large future
studies—for their prognostic value.
After the search cut-off date imposed by the IPD meta-
analysis criteria, another study was published recently
focusing on CNS-PNET/pineoblastoma only in pediatric
patients [17]. By evaluating the genomic array data which are
available from NCBI’s Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/; accession number GSE12370),
we were able to generate CNA profiles for 38 patients (8 of
whom had pineoblastoma, and 30 had a CNS-PNET; CGH
data from 35 CNS-PNET cases were listed, 5 recurrent
tumors were paired with a primary sample from the same
patient) and 1 CNS-PNET cell line. Here, as in our IPD meta-
analysis, pineoblastoma exhibited CNA profiles roughly
comparable to subsets of cases identified as CNS-PNET as
shown in the Supplementary Fig. 5 a, b.
The approach of an IPD meta-analysis—a specific
method of systematic review based on a systematic
search—is in our opinion both necessary and efficient to
increase the patient number in rare tumor diseases. By
using IPD, we may overcome many of the limitations of
systematic reviews (e.g., poor quality of data can be
improved by updating the information). We used common
inclusion and exclusion criteria for each individual case. In
addition, we have performed a quality assessment of
genomic data by reassessment of each individual case by
two researchers (M.B. and H.C.). Methods to assess
genomic CNAs are standardized and reproducible as
demonstrated in previous reports (e.g., [11, 12]). Moreover,
by including unpublished data [25], we aimed to reduce the
risk for publication bias [20]. Of course, the inclusion of a
larger number of unpublished cases would have been
desirable, and a ‘‘pooling’’ of such data has an exceptional
value for rare diseases. Of note, IPD meta-analyses usually
take longer than conventional systematic review, and
obtaining IPD is time-consuming [20]. Therefore, it is not
possible to include all very recent studies, and many IPD
J Neurooncol (2012) 109:415–423 421
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meta-analyses are conducted on a cyclical basis with data
collection, quality assessment, analyses, and dissemination
of results taking place every few years [18], because by the
time of the final analysis of the pooled data new cases are
already available. We acknowledge some limitations of our
study which is based on original data produced over a time
period of several years. As shown in Supplementary
Table 1, the WHO classification of tumors of the CNS has
changed during this period. Moreover, in recent years, the
staging has improved, as have surgical procedures and non-
surgical treatment options of patients with CNS-PNET and
tumors of the pineal region. Regarding genomic analysis
methods, high-resolution profiling by genomic copy num-
ber arrays or whole genome sequencing could provide a
higher sensitivity for the detection of hitherto undetected
CNA. However, the main limitations in identifying robust
CNA markers with prognostic value are in the limited
number of samples and associated clinical datasets avail-
able for such analyses.
In summary, CNS-PNET and low grade tumors of the
pineal region are characterized by differences in CNA
profiles. In this respect, pineoblastoma fit readily into the
genomically heterogeneous group of CNS-PNET with a
complex karyotype. Although not necessarily displayed by
each individual case, typical CNA profiles underline the
differing biological background of these entities. Our
results provide evidence that young age, high CNA com-
plexity, and potentially also several specific CNAs may
have an impact on OS.
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